Completed Transactions

Completed Transactions > Healthcare & Life Sciences > MediSuite Acquired By ADDvise Group AB

MediSuite Acquired By ADDvise Group AB



Aug 2021


North Carolina

We are pleased to announce the sale of our client, MediSuite, LLC, to ADDvise Group AB. The acquisition closed August 4, 2021.

Located in Cary, North Carolina, MediSuite is a national, mail-order pharmacy, MediSuite provides men’s health generic drugs at significant cost savings. MediSuite only dispenses FDA-approved pharmaceuticals. MediSuite’s most popular drugs are the generics of Viagra® (Sildenafil) and Cialis® (Tadalafil).

ADDvise Group AB (ADDvise), headquartered in Stockholm, Sweden, is a leading supplier of equipment and services to healthcare and research facilities. The Group’s subsidiaries are organized into two business areas: LAB and HEALTHCARE. Sales are global.

The Group has a clear acquisition strategy of increasing shareholder value through growth – both geographically and by product range. ADDvise shares are listed on Nasdaq First North Growth Market.

MediSuite will be consolidated into ADDvise’s financial reporting as of August 2021. The local management of MediSuite and its operational business structure will remain unchanged pursuant to ADDvise's decentralized structure and the corporate governance of the group. ADDvise welcomes MediSuite to the group.

Generational Equity Executive Managing Director, M&A-Technology Practice Leader, David Fergusson, and his team led by Senior M&A Advisor, Gene Gall, with the support of Vice President Mergers & Acquisitions, Alex Mironov, successfully closed the deal. Executive Managing Director Bill Kushnir established the initial relationship with MediSuite.

“MediSuite is licensed in 48 states and the District of Columbia which gives ADDvise Group a perfect launching platform for their healthcare division in the United States,” said Gall.

If you would like to explore other transactions our associates have supported in this industry, visit our dedicated Healthcare & Life Sciences M&A Deals page.